Novartis and Yuhan Corporation will co-promote a new COPD complex
‘Xoterna Breezhaler,’ the fixed capacity complex consisting of two bronchodilators, the long acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, is going to be launched as the phase-1 maintenance therapy drug to relieve the chronic obstructive pul...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
